The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”
Background: Blood uric acid level indicates an emerging biomarker in Parkinson's disease (PD). This study aimed to evaluate longitudinal uric acid levels among different kinds of glucocerebrosidase (GBA) mutations and to compare it among sporadic PD, genetic cohort Parkinson's disease (GEN...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Clinical Parkinsonism & Related Disorders |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590112522000482 |
| _version_ | 1797827802845675520 |
|---|---|
| author | Mehrdad Mozafar Sina Kazemian Elahe Hoseini Mohammad Mohammadi Rojina Alimoghadam Mahan Shafie Mahsa Mayeli |
| author_facet | Mehrdad Mozafar Sina Kazemian Elahe Hoseini Mohammad Mohammadi Rojina Alimoghadam Mahan Shafie Mahsa Mayeli |
| author_sort | Mehrdad Mozafar |
| collection | DOAJ |
| description | Background: Blood uric acid level indicates an emerging biomarker in Parkinson's disease (PD). This study aimed to evaluate longitudinal uric acid levels among different kinds of glucocerebrosidase (GBA) mutations and to compare it among sporadic PD, genetic cohort Parkinson's disease (GENPD), genetic cohort unaffected (GENUN), and healthy control (HC) patients. Methods: We conducted a study on 654 individuals from the Parkinson's progression markers initiative (PPMI) database. Baseline characteristics, uric acid levels, movement disorder society unified Parkinson's disease rating scale III (MDS-UPDRS III), Hoehn and Yahr Parkinson stage (H&Y stage), and DaT scan specific binding ratio (SBR) data were obtained. Different GBA mutations were collected and categorized into three groups. Longitudinal measurements of uric acid and MDS-UPDRS III score were evaluated during 3-years of follow-up. Result: GENPD cohort exhibited a greater MDS-UPDRS III score, H&Y stage, and lower SBR in the right caudate, left caudate, and right putamen compared to sporadic PD. Baseline uric acid level was similar among all groups and different GBA variants. After adjustment for age, sex, and body mass index, the uric acid level was significantly lower in the GENPD group than in HC during year 2 (P-value: 0.009). No significant longitudinal differences were detected for the MDS-UPDRS III score and three groups of GBA mutations. Conclusion: This is the first study to assess uric acid levels and MDS-UPDRS III scores among different GBA mutation variants within 3 years of follow-up. We found similar clinical characteristics among different subtypes of GBA mutations. |
| first_indexed | 2024-04-09T12:54:12Z |
| format | Article |
| id | doaj.art-ccba40911e9b450489a2b05feae32fed |
| institution | Directory Open Access Journal |
| issn | 2590-1125 |
| language | English |
| last_indexed | 2024-04-09T12:54:12Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Parkinsonism & Related Disorders |
| spelling | doaj.art-ccba40911e9b450489a2b05feae32fed2023-05-14T04:29:28ZengElsevierClinical Parkinsonism & Related Disorders2590-11252023-01-018100177The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”Mehrdad Mozafar0Sina Kazemian1Elahe Hoseini2Mohammad Mohammadi3Rojina Alimoghadam4Mahan Shafie5Mahsa Mayeli6NeuroTRACT Association, Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran; School of Medicine, Tehran University of Medical Sciences, Tehran, IranNeuroTRACT Association, Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IranNeuroTRACT Association, Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran; Medical Imaging Department, AMT School, Isfahan Medical Sciences University, Isfahan, IranNeuroTRACT Association, Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, IranNeuroTRACT Association, Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, IranNeuroTRACT Association, Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran; School of Medicine, Tehran University of Medical Sciences, Tehran, IranNeuroTRACT Association, Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran; Iranian Center of Neurological Research, Imam Khomeini Hospital Complex, Tehran, Iran; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Corresponding author.Background: Blood uric acid level indicates an emerging biomarker in Parkinson's disease (PD). This study aimed to evaluate longitudinal uric acid levels among different kinds of glucocerebrosidase (GBA) mutations and to compare it among sporadic PD, genetic cohort Parkinson's disease (GENPD), genetic cohort unaffected (GENUN), and healthy control (HC) patients. Methods: We conducted a study on 654 individuals from the Parkinson's progression markers initiative (PPMI) database. Baseline characteristics, uric acid levels, movement disorder society unified Parkinson's disease rating scale III (MDS-UPDRS III), Hoehn and Yahr Parkinson stage (H&Y stage), and DaT scan specific binding ratio (SBR) data were obtained. Different GBA mutations were collected and categorized into three groups. Longitudinal measurements of uric acid and MDS-UPDRS III score were evaluated during 3-years of follow-up. Result: GENPD cohort exhibited a greater MDS-UPDRS III score, H&Y stage, and lower SBR in the right caudate, left caudate, and right putamen compared to sporadic PD. Baseline uric acid level was similar among all groups and different GBA variants. After adjustment for age, sex, and body mass index, the uric acid level was significantly lower in the GENPD group than in HC during year 2 (P-value: 0.009). No significant longitudinal differences were detected for the MDS-UPDRS III score and three groups of GBA mutations. Conclusion: This is the first study to assess uric acid levels and MDS-UPDRS III scores among different GBA mutation variants within 3 years of follow-up. We found similar clinical characteristics among different subtypes of GBA mutations.http://www.sciencedirect.com/science/article/pii/S2590112522000482Glucocerebrosidase mutationsUric acid levelsDaT scan specific binding ratioParkinson’s disease |
| spellingShingle | Mehrdad Mozafar Sina Kazemian Elahe Hoseini Mohammad Mohammadi Rojina Alimoghadam Mahan Shafie Mahsa Mayeli The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” Clinical Parkinsonism & Related Disorders Glucocerebrosidase mutations Uric acid levels DaT scan specific binding ratio Parkinson’s disease |
| title | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
| title_full | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
| title_fullStr | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
| title_full_unstemmed | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
| title_short | The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker” |
| title_sort | glucocerebrosidase mutations and uric acid levels in parkinson s disease a 3 years investigation of a potential biomarker |
| topic | Glucocerebrosidase mutations Uric acid levels DaT scan specific binding ratio Parkinson’s disease |
| url | http://www.sciencedirect.com/science/article/pii/S2590112522000482 |
| work_keys_str_mv | AT mehrdadmozafar theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT sinakazemian theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT elahehoseini theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mohammadmohammadi theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT rojinaalimoghadam theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mahanshafie theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mahsamayeli theglucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mehrdadmozafar glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT sinakazemian glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT elahehoseini glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mohammadmohammadi glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT rojinaalimoghadam glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mahanshafie glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker AT mahsamayeli glucocerebrosidasemutationsanduricacidlevelsinparkinsonsdiseasea3yearsinvestigationofapotentialbiomarker |